Previous 10 | Next 10 |
home / stock / mdgef / mdgef news
The following slide deck was published by Medigene AG in conjunction with this Read more ...
MediGene AG ( OTCPK:MDGEF ): Q2 GAAP EPS of -€0.35. Revenue of €3.54k (+68% Y/Y) Press Release More news on: Medigene AG, Earnings news and commentary, Tech stocks news, ,
The summer holiday season has begun but stocks, despite taking a breather following Trump's surprise exit of the U.S. - China trade negotiations, have resumed their upward trend and set new records towards the end of the month. In terms of buying and selling it was a rather quiet month for m...
It's May, and this is the best time of the year for a German dividend investor, as this is the month where most of Germany's companies distribute their annual dividends. As such, it was no surprise that May set a new record in dividend income, but I am still baffled by the amount and the growt...
It's been a rather mediocre month for my income generation in April. Dividend income just barely topped the $200-mark as the overall portfolio rallied to new highs despite some heavy earnings-related blows on my top holdings. Going forward, I will try to better balance my dividend income and s...
We all love records, and March was a record month, as for the very first time I was able to hit $400 in dividend income, the next milestone reached on my long journey towards financial independence. Markets were rallying strongly in March and posting one of their best performances ever since...
Deals and Financings Cytovant Sciences, a China cell therapy startup, announced a $1 billion partnership with Germany's Medigene (MDGEF) to develop four of Medigene's T cell immunotherapy products in China (see story ). Cytovant paid $10 million upfront for the products, and agreed to make ...
Sinovant Sciences and Roivant Sciences launch Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia. More news on: Medigene AG, Healthcare stocks news, Read more ...
Medigene AG (MDGEF) Q4 2018 Earnings Conference Call March 27, 2019 09:00 AM ET Company Participants Julia Hofmann - Head, Public & Investor Relations Dolores Schendel - Chief Executive Officer and Chief Scientific Officer Kai Pinkernell - Chief Medical Officer and Chief Deve...
The following slide deck was published by Medigene AG in conjunction with their 2018 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...